Skip to main content
  • First Short-Term Follow-Up of Mistral Tricuspid Valve Repair Finds Significant Improvement in Severe TR

    A short-term follow-up of the first-in-human study for the Mistral tricuspid valve repair device found that patients with severe tricuspid regurgitation (TR) – a group with no standard-of-care options – had significant improvements in their condition.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details